8622 Stock Overview An investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China, Hong Kong, and Canada. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Huakang Biomedical Holdings Company Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Huakang Biomedical Holdings Historical stock prices Current Share Price HK$0.30 52 Week High HK$0.41 52 Week Low HK$0.08 Beta 0.11 1 Month Change 122.22% 3 Month Change 73.41% 1 Year Change 78.57% 3 Year Change 20.00% 5 Year Change 69.49% Change since IPO -36.17%
Recent News & Updates
Huakang Biomedical Holdings Company Limited Announces Board Changes Jan 22 Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 12.6 million. Jan 01
New minor risk - Share price stability Dec 24
Huakang Biomedical Holdings Company Limited Announces the Appointment of Shih Mei Ling as Independent Non-Executive Director Dec 03
New major risk - Market cap size Nov 29
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023) Aug 17 See more updates
Huakang Biomedical Holdings Company Limited Announces Board Changes Jan 22 Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 12.6 million. Jan 01
New minor risk - Share price stability Dec 24
Huakang Biomedical Holdings Company Limited Announces the Appointment of Shih Mei Ling as Independent Non-Executive Director Dec 03
New major risk - Market cap size Nov 29
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023) Aug 17
Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024 Aug 06
New minor risk - Share price stability Jun 13
Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable Jun 11
Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024 May 19 Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million. Apr 03
Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022) Mar 30 Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million. Mar 22
Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19 Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million. Feb 09
Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million. Feb 02
New minor risk - Shareholder dilution Feb 01 Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million. Feb 01
Chairman of the Board recently sold HK$815k worth of stock Jan 13 Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million. Jan 09
Insufficient new directors Jan 02
Vice Chairman recently sold HK$2.9m worth of stock Dec 30
Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022) Nov 16
Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023 Nov 04
Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022) Aug 10
Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee Aug 03
Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023 Jul 29
First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022) May 15
Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021) Mar 26
Vice Chairman recently sold HK$101k worth of stock Jan 05
Less than half of directors are independent Nov 16 Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million. Sep 07
Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021) Aug 10
Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022 Jul 28
Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022 May 14
First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021) May 12
Less than half of directors are independent Apr 27
Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020) Mar 28
Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021 Mar 06
Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020) Nov 10
Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020) Aug 18
First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020) May 12
Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019) Mar 27
Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021 Mar 13
Huakang Biomedical Holdings Company Limited Announces Management Changes Dec 18
Third quarter 2020 earnings released: CN¥0.001 loss per share Nov 12
Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020 Oct 30
Earnings released Aug 13 Shareholder Returns 8622 HK Medical Equipment HK Market 7D -10.4% 5.5% 1.9% 1Y 78.6% -11.2% 20.8%
See full shareholder returns
Return vs Market: 8622 exceeded the Hong Kong Market which returned 20.8% over the past year.
Price Volatility Is 8622's price volatile compared to industry and market? 8622 volatility 8622 Average Weekly Movement 23.5% Medical Equipment Industry Average Movement 6.1% Market Average Movement 6.5% 10% most volatile stocks in HK Market 13.9% 10% least volatile stocks in HK Market 3.0%
Stable Share Price: 8622's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8622's weekly volatility has increased from 17% to 24% over the past year.
About the Company Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China, Hong Kong, and Canada. The company provides male fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; and auxiliary reproductive supplies and equipment. It also offers healthcare products and supplements under the Nutronic brand through its websites, including nutronic.ca and nutronic.hk; offline channels, such as Eugenebaby and green price shops; and e-commerce platforms comprising Tmall, JD.com, Amazon, HKTVmall, Eugenebaby, etc. The company sells its products directly to hospitals and medical institutions, as well as to distributors.
Show more Huakang Biomedical Holdings Company Limited Fundamentals Summary How do Huakang Biomedical Holdings's earnings and revenue compare to its market cap? 8622 fundamental statistics Market cap HK$150.14m Earnings (TTM ) -HK$6.56m Revenue (TTM ) HK$26.96m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8622 income statement (TTM ) Revenue CN¥25.08m Cost of Revenue CN¥8.54m Gross Profit CN¥16.54m Other Expenses CN¥22.64m Earnings -CN¥6.11m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.012 Gross Margin 65.94% Net Profit Margin -24.34% Debt/Equity Ratio 5.1%
How did 8622 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/25 21:20 End of Day Share Price 2025/01/24 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Huakang Biomedical Holdings Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
